Aptinyx (NASDAQ:APTX – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02, Fidelity Earnings reports. During the same period in the prior year, the firm posted ($0.22) earnings per share.
Aptinyx stock traded up $0.10 during midday trading on Friday, reaching $0.70. The company’s stock had a trading volume of 136,370 shares, compared to its average volume of 312,910. Aptinyx has a 52 week low of $0.57 and a 52 week high of $4.73. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $1.78 and a 200-day moving average price of $2.43. The stock has a market cap of $47.40 million, a PE ratio of -0.59 and a beta of 1.46.
Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp grew its holdings in shares of Aptinyx by 203.7% during the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock worth $498,000 after purchasing an additional 147,357 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aptinyx by 8.4% during the first quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock worth $4,459,000 after purchasing an additional 152,943 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Aptinyx by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 140,711 shares of the company’s stock worth $320,000 after purchasing an additional 16,774 shares during the last quarter. Cetera Advisor Networks LLC bought a new stake in shares of Aptinyx during the first quarter worth about $92,000. Finally, BlackRock Inc. grew its holdings in shares of Aptinyx by 1.5% during the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company’s stock worth $3,669,000 after purchasing an additional 20,928 shares during the last quarter. Institutional investors own 55.97% of the company’s stock.
About Aptinyx (Get Rating)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.